1-(3′-fluoro-[1,1′-biphenyl]-2-yl)ethanone | 893739-19-0

• 物质功能分类: 有机原料 - 酮类化合物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(3′-fluoro-[1,1′-biphenyl]-2-yl)ethanone
• 英文别名: 1-(3'-fluoro-[1,1'-biphenyl]-2-yl)ethan-1-one；2'-(3'-fluorophenyl)acetophenone；1-(3'-Fluoro[1,1'-biphenyl]-2-yl)ethanone；1-[2-(3-fluorophenyl)phenyl]ethanone
• CAS: 893739-19-0
• 化学式: C₁₄H₁₁FO
• 分子量: 214.239
• InChiKey: NYNVMSOFFTZYSZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(3′-fluoro-[1,1′-biphenyl]-2-yl)ethanone 在 吡啶 、 2,2,6,6-四甲基哌啶氧化物 、 盐酸羟胺 、 potassium hydroxide 作用下， 以 乙醇 、 水 、 乙腈 为溶剂， 生成 2-fluoro-6-methylphenanthridine
  参考文献：
  名称：

  阴极材料决定联芳基酮肟化学C-H官能化的产物选择性

  摘要：

  多环N-杂芳族化合物及其相应的N-氧化物的合成是通过联芳基酮肟的电化学CH功能化开发的。当使用Pt阴极时，肟底物会经历脱氢环化反应，从而导致空前地获得各种N-杂芳族N-氧化物。通过顺序地阳极促进的脱氢环化作用和最初形成的N-氧化物中N-O键的阴极裂解，采用Pb阴极，将电合成的产物切换为脱氧的N-杂芳族化合物。

  DOI：

  10.1002/anie.201809679
• 作为产物：
  描述：

  3'-fluoro-[1,1'-biphenyl]-2-carbaldehyde 在 2-碘酰基苯甲酸 作用下， 以 四氢呋喃 、 乙酸乙酯 为溶剂， 生成 1-(3′-fluoro-[1,1′-biphenyl]-2-yl)ethanone
  参考文献：
  名称：

  阴极材料决定联芳基酮肟化学C-H官能化的产物选择性

  摘要：

  多环N-杂芳族化合物及其相应的N-氧化物的合成是通过联芳基酮肟的电化学CH功能化开发的。当使用Pt阴极时，肟底物会经历脱氢环化反应，从而导致空前地获得各种N-杂芳族N-氧化物。通过顺序地阳极促进的脱氢环化作用和最初形成的N-氧化物中N-O键的阴极裂解，采用Pb阴极，将电合成的产物切换为脱氧的N-杂芳族化合物。

  DOI：

  10.1002/anie.201809679

文献信息

• [EN] MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO<br/>[FR] MODULATEURS DU RÉCEPTEUR DE PROSTACYCLINE (PGI2) UTILES POUR LE TRAITEMENT DE TROUBLES ASSOCIÉS À CELUI-CI
  申请人：ARENA PHARM INC

  公开号：WO2010077275A1

  公开（公告）日：2010-07-08

  Cyclohexane derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).

  环己烷衍生物的公式Ia和调节PGI2受体活性的药物组合物。本发明的化合物和药物组合物适用于治疗以下疾病：肺动脉高压（PAH）及相关疾病；血小板聚集；冠心病；心肌梗死；短暂性脑缺血发作；心绞痛；中风；缺血再灌注损伤；再狭窄；房颤；在血管成形术或冠状动脉搭桥手术个体或房颤患者中形成血栓；动脉粥样硬化；动脉血栓形成；哮喘或其症状；糖尿病相关疾病，如糖尿病周围神经病变、糖尿病肾病或糖尿病视网膜病变；青光眼或其他眼内压异常的眼病；高血压；炎症；银屑病；银屑病关节炎；类风湿性关节炎；克罗恩病；移植排斥；多发性硬化症；系统性红斑狼疮（SLE）；溃疡性结肠炎；缺血再灌注损伤；再狭窄；动脉粥样硬化；痤疮；1型糖尿病；2型糖尿病；败血症；慢性阻塞性肺病（COPD）。
• O-Phenyl Chalcone Compounds And Preparation Method And Use Thereof
  申请人：Sun Yat-Sen University

  公开号：US20160333033A1

  公开（公告）日：2016-11-17

  Disclosed are an o-phenyl chalcone compounds and preparation methods and uses thereof. The o-phenyl chalcone compounds are capable of inhibiting the aggregation of microtubules in tumor cells and influencing the mitosis of the cells, and have a high antitumor activity. The compounds also have inhibitory activity against proliferation on various tumor cells, such as a human ovary cancer cell A2780, a human colon cancer cell HCT8, a human breast cancer cell MCF7, a human lung cancer cell A549, a human colon cancer cell SW480, a human nasopharyngeal carcinoma cell CNE2, a human liver cancer cell HepG2 and the like at nanomole concentrations.

  揭示了一种 o-苯基查尔酮化合物及其制备方法和用途。这些 o-苯基查尔酮化合物能够抑制肿瘤细胞微管的聚集，影响细胞的有丝分裂，并具有较高的抗肿瘤活性。这些化合物还在纳摩尔浓度下对各种肿瘤细胞的增殖具有抑制活性，如人卵巢癌细胞A2780、人结肠癌细胞HCT8、人乳腺癌细胞MCF7、人肺癌细胞A549、人结肠癌细胞SW480、人鼻咽癌细胞CNE2、人肝癌细胞HepG2等。
• [EN] NOVEL DIHYDROPYRIMIDIN-2(1H)-ONE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS DIHYDROPYRIMIDINE-2(1H)-ONES EN TANT QU'INHIBITEURS DE LA S-NITROSOGLUTATHION RÉDUCTASE
  申请人：N30 PHARMACEUTICALS LLC

  公开号：WO2011038204A1

  公开（公告）日：2011-03-31

  The present invention is directed to novel dihydropyrimidin-2(1H)-one compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same.

  本发明涉及一种新型二氢嘧啶-2(1H)-酮化合物，可用作S-亚硝基谷胱甘肽还原酶（GSNOR）抑制剂，包括这些化合物的药物组合物，以及制备和使用这些化合物的方法。
• Electrochemical Decarboxylative Cyclization of α‐Amino‐Oxy Acids to Access Phenanthridine Derivatives
  作者：Yanling Zhan、Changhui Dai、Zitong Zhu、Ping Liu、Peipei Sun

  DOI：10.1002/asia.202101388

  日期：2022.3.14

  compounds found in pharmaceuticals and natural products. Herein, an efficient electrochemical decarboxylative cyclization of α-amino-oxy acids to synthesize phenanthridine derivatives was developed. This reaction proceeded through iminyl radical formation cascade intramolecular cyclization from readily available materials under transition-metal-free and mild conditions.

  菲啶是一类重要的杂环化合物，存在于药物和天然产物中。在此，开发了一种高效的 α-氨基氧基酸电化学脱羧环化合成菲啶衍生物。该反应通过在无过渡金属和温和条件下从容易获得的材料中形成亚氨基自由基级联分子内环化进行。
• Synthesis and evaluation of anticancer activity of BOC26P, an ortho-aryl chalcone sodium phosphate as water-soluble prodrugs in vitro and in vivo
  作者：Cuige Zhu、Ruimin Wang、Weichao Zheng、Daoyuan Chen、Xin Yue、Yingnan Cao、Wenjing Qin、Haixia Sun、Youqiao Wang、Ziyi Liu、Baojian Li、Jun Du、Xianzhang Bu、Binhua Zhou

  DOI：10.1016/j.biopha.2017.10.006

  日期：2017.12

  Major limitations of chalcones as clinical anticancer agents are water insolubility and poor bioavailability, which may be improved by a classic phosphate prodrug strategy that targets non-specific alkaline phosphatase (ALP) for releasing the parent drug in vivo. In this study, we found that BOC26P, a phosphate prodrug of chalcone OC26, exhibits excellent water solubility and improved plasma concentration in vivo by either i.v. or p.o. compared with the parent drug. In pace with decreased inhibitory activity of BOC26P against microtubule polymerization in vitro and in cells, the antiproliferative activity of BOC26P is attenuated in A549 and HLF cells. However, the antitumor effect of BOC26P increases in an A549 xenograft model as compared to the equimolar concentration of OC26, suggesting that complex tumor microenvironment would be another important influence factor to regulate the antitumor activity of BOC26P in vivo. In conclusion, these observations showed that the traditional phosphate prodrug strategy would be a promising and easy method to increase water solubility and anticancer activity of chalcones for the clinical developments of anticancer agents.